综述:功能性消化不良与妊娠——特殊人群中的影响与管理
约10%的美国成人符合罗马IV功能性消化不良(FD)标准,女性患病率显著更高,且50岁以下女性患病率更高,提示患者多处于育龄期。本文原计划系统综述FD与妊娠的相互作用及围产期和产后管理,但因缺乏妊娠期FD特异性数据,改为叙述性综述,将现有FD干预措施外推至妊娠人群,并指出当前知识空白。
要点
- 约10%美国成人符合罗马IV FD标准,女性患病率显著更高,50岁以下女性患病率更高。
- 妊娠期FD管理缺乏研究或循证指南,缺乏罗马IV FD特异性妊娠数据。
- 作者认为患者理想情况下应将治疗最小化至母乳喂养结束后。
核心结论
- 尽管妊娠期FD治疗知识匮乏,服务提供者可通过与患者提前规划来减轻这种不确定性。
- 作者认为患者理想情况下应将治疗最小化至母乳喂养结束后。
- 跨学科资源可用于确保最小风险干预最大化,而风险较高的干预如必要则需患者和医疗团队双方认可其合理性。
- 未来研究应继续阐明FD与妊娠的机制关系,同时谨慎扩展对妊娠期FD患者有前景且安全疗法的前瞻性研究。
研究设计与样本
- 原计划对FD与妊娠的相互作用及围产期和产后FD管理进行系统综述,使用当前生活方式、药物、非药物和替代医学干预。
- 因缺乏妊娠期罗马IV FD特异性数据,改为叙述性综述,将现有FD干预外推至妊娠人群。
- 在可能处使用最高级别可用证据或官方指南,常需综合这些干预在其他疾病妊娠期间的治疗与安全性证据。
主要发现
- 约10%的美国成人符合罗马IV FD标准,女性患病率显著更高。
- FD在50岁以下女性中患病率更高,提示受影响女性可能处于生育年龄。
- 缺乏妊娠期FD管理的研究或循证指南。
- 缺乏妊娠期罗马IV FD特异性数据。
临床怎么用
- 作者认为服务提供者可通过与患者提前规划来减轻妊娠期FD治疗的不确定性。
- 作者认为患者理想情况下应将治疗最小化至母乳喂养结束后。
- 作者认为跨学科资源可用于确保最小风险干预最大化,风险较高的干预如必要需患者和医疗团队双方认可其合理性。
局限性
- 缺乏妊娠期FD管理的研究或循证指南。
- 缺乏妊娠期罗马IV FD特异性数据,故改为叙述性综述。
- 当前存在大量知识空白,需要进一步研究以安全管理的妊娠期FD患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Around 10% of Americans meet the Rome IV criteria for functional dyspepsia (FD), with a significantly higher rate in women. FD also has a higher prevalence in women below the age of 50, suggesting that women who are affected are likely to be of reproductive age. Unfortunately, there is a lack of research or evidence-based guidelines on managing FD in pregnancy. AIMS AND METHODS: To address this issue, we aimed to perform a systematic review of the interactions between FD and pregnancy and managing pre-existing FD in the peripartum and post-partum phases using current lifestyle, pharmacological, non-pharmacological and alternative medicine interventions. RESULTS: Due to the lack of Rome IV FD-specific data in pregnancy, we instead performed a narrative review on how existing FD interventions could be extrapolated to the pregnant population. Where possible we use the highest level of available evidence or official guidelines to answer these questions, which often involves synthesising treatment and safety evidence of these interventions in other diseases during pregnancy. Finally, we highlight current substantial knowledge gaps requiring further research for the safe management of a pregnant patient with pre-existing FD. CONCLUSIONS: Overall, despite the paucity of knowledge of treating FD during pregnancy, providers can mitigate this uncertainty by planning ahead with the patient. Patients should ideally minimise treatment until after breastfeeding. However, interdisciplinary resources are available to ensure that minimal-risk interventions are maximised, while interventions with more risks, if necessary, are justifiable by both the patient and the care team. Future investigations should continue to elicit the mechanistic relationship between FD and pregnancy while cautiously expanding prospective research on promising and safe therapies in pregnant patients with pre-existing FD.
引用
- Liu BD, Starkey M, Virani A, et al. Review article: Functional dyspepsia and pregnancy-Effects and management in a special population. Aliment Pharmacol Ther. 2023. PMID: 37129241. doi:10.1111/apt.17534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。